Suchergebnisse - "de Tute, Ruth M"

PubPharm (26)

1

Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma : results from the NCRI Myeloma X (intensive) trial

enthalten in: Bone marrow transplantation | 2024

von de Tute, R. | Cook, G. | Cairns, D. | +12

2

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Kaiser, M. | Hall, A. | Walker, K. | +17

3

Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signature

enthalten in: bioRxiv.org | 2023

von Walker, I. | D’arcy, V. | Khandelwal, G. | +24

4

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON) : a randomised, phase 2, non-inferiority trial

enthalten in: The Lancet. Haematology | 2023

von Yong, K. | Wilson, W. | de Tute, R. | +18

CommentIn: Lancet Haematol. 2023 Feb;10(2):e80-e82. - PMID 36529146

5

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma : Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von de Tute, R. | Pawlyn, C. | Cairns, D. | +14

CommentIn: J Clin Oncol. 2022 Sep 1;40(25):2863-2866. - PMID 35772041

6

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy : results from a multicenter, phase II, randomized, controlled trial (MUKfive)

enthalten in: Haematologica | 2021

von Yong, K. | Hinsley, S. | Auner, H. | +16

CommentIn: Haematologica. 2021 Oct 01;106(10):2539-2541. - PMID 33910336

7

Novel somatic mutations in UBA1 as a cause of VEXAS syndrome

enthalten in: Blood | 2021

von Poulter, J. | Collins, J. | Cargo, C. | +12

CommentOn: N Engl J Med. 2020 Dec 31;383(27):2628-2638. - PMID 33108101

8

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+) : Interim analysis of an open-label randomised controlled trial

enthalten in: PLoS medicine | 2021

von Jackson, G. | Pawlyn, C. | Cairns, D. | +21

9

Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse

enthalten in: British journal of haematology | 2019

von Cohen, O. | Counsell, N. | Rabin, N. | +13

10

Minimal residual disease following autologous stem cell transplant in myeloma : impact on outcome is independent of induction regimen

enthalten in: Haematologica | 2016

von de Tute, R. | Rawstron, A. | Gregory, W. | +9